Literature DB >> 20225664

Should we routinely measure low-density and high-density lipoprotein subclasses?

Manfredi Rizzo1, Kaspar Berneis, Aleksandra Zeljkovic, Jelena Vekic.   

Abstract

Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) plasma populations are composed of heterogeneous subfractions that are different in size, density and protein/lipid content. There is increasing evidence that small, dense LDL particles are strongly associated with higher cardiovascular disease risk. Similarly, several studies have investigated whether smaller HDL particles are more protective than their larger counterparts and more recent findings suggest that small, dense HDL has significantly higher atheroprotective activity than larger HDL. Yet, certain impairments of the protein/lipid content in small, dense HDL may decrease its antiatherogenic capacity or even induce pro-atherogenic properties. Therefore, it seems that the small, dense phenomenon applies to both LDL and HDL particles. Measurement of LDL and HDL cholesterol concentrations has proven clinical utility, while the usefulness of LDL and HDL subclasses determination in clinical practice offers grounds for further exploration. However, LDL and HDL particles characterisation requires either special equipment or a lengthy analytical time and is, therefore, still unsuitable for general clinical use. It remains to be established whether lipoprotein subclasses should be analyzed in routine practice, although their assessment in high-risk subjects could be recommended.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20225664

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  9 in total

1.  Associations of lipoprotein subclasses and oxidative stress status in pulmonary and pulmonary plus extrapulmonary sarcoidosis.

Authors:  Jasmina Ivaniševic; Jelena Vekic; Aleksandra Zeljkovic; Aleksandra Stefanovic; Jelena Kotur-Stevuljevic; Vesna Spasojevic-Kalimanovska; Slavica Spasic; Violeta Vucinic-Mihailovic; Jelica Videnovic-Ivanov; Zorana Jelic-Ivanovic
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

Review 2.  Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL.

Authors:  Jelena Vekic; Aleksandra Zeljkovic; Arrigo F G Cicero; Andrej Janez; Anca Pantea Stoian; Alper Sonmez; Manfredi Rizzo
Journal:  Medicina (Kaunas)       Date:  2022-02-16       Impact factor: 2.430

3.  Effect of propolis and N-acetylcysteine supplementation on lipoprotein subclasses distribution and paraoxonase 1 activity in subjects with acute respiratory infection.

Authors:  Jelena Vekić; Jasmina Ivanišević; Aleksandra Zeljković; Vesna Spasojević-Kalimanovska; Nataša Bogavac-Stanojević; Marija Mihajlović; Jelena Janać; Sanja Vujčić; Milica Miljković; Dejan Zujović; Jelena Kotur-Stevuljević
Journal:  J Med Biochem       Date:  2020-10-02       Impact factor: 3.402

4.  Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia.

Authors:  Manfredi Rizzo; Giovam Battista Rini
Journal:  Arch Med Sci       Date:  2011-03-08       Impact factor: 3.318

5.  The effects of statins on blood pressure: current knowledge and future perspectives.

Authors:  Manfredi Rizzo; Giuseppe Montalto; Maciej Banach
Journal:  Arch Med Sci       Date:  2012-02-29       Impact factor: 3.318

Review 6.  Hashimoto Thyroiditis and Dyslipidemia in Childhood: A Review.

Authors:  Rade Vukovic; Aleksandra Zeljkovic; Biljana Bufan; Vesna Spasojevic-Kalimanovska; Tatjana Milenkovic; Jelena Vekic
Journal:  Front Endocrinol (Lausanne)       Date:  2019-12-10       Impact factor: 5.555

Review 7.  A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies.

Authors:  Jelena Vekic; Aleksandra Zeljkovic; Khalid Al Rasadi; Mustafa Cesur; José Silva-Nunes; Anca Pantea Stoian; Manfredi Rizzo
Journal:  Metabolites       Date:  2022-01-24

Review 8.  Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL.

Authors:  Jelena Vekic; Aleksandra Zeljkovic; Aleksandra Stefanovic; Natasa Bogavac-Stanojevic; Ioannis Ilias; José Silva-Nunes; Anca Pantea Stoian; Andrej Janez; Manfredi Rizzo
Journal:  Pharmaceutics       Date:  2022-04-09       Impact factor: 6.525

9.  Effects of Apnea, Obesity, and Statin Therapy on Proprotein Convertase Subtilisin/Kexin 9 Levels in Patients with Obstructive Sleep Apnea.

Authors:  Ana Milojević; Marija Zdravković; Milica Brajković; Lidija Memon; Vera Gardijan; Jelena Vekić; Aleksandra Zeljković; Aleksandra Stefanović; Marija Mihajlović; Jasmina Ivanišević; Nataša Bogavac-Stanojević; Vojislav Radosavljević; Vesna Spasojević-Kalimanovska; Ana Ninić
Journal:  Med Princ Pract       Date:  2022-03-15       Impact factor: 2.132

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.